Inhibrx Biosciences, Inc. Common Stock (INBX) is a publicly traded Healthcare sector company. As of October 26, 2026, INBX trades at $90.35 with a market cap of $1.37B and a P/E ratio of -10.57. INBX moved -2.54% today. Year to date, INBX is +18.20%; over the trailing twelve months it is +229.27%. Its 52-week range spans $10.81 to $155.29. Analyst consensus is strong buy with an average price target of $266.67. Rallies surfaces INBX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Inhibrx Biosciences publishes HexAgon-HN phase 2 results presentation: Inhibrx Biosciences published phase 2 results for ordastobart with pembrolizumab in recurrent or metastatic head-and-neck cancer. The combination’s confirmed response rate was 48.3%, versus 26.5% with pembrolizumab alone, while grade 3 or higher treatment-related adverse events occurred in 48.4%, versus 11.8%.
| Metric | Value |
|---|---|
| Price | $90.35 |
| Market Cap | $1.37B |
| P/E Ratio | -10.57 |
| EPS | $-9.04 |
| Dividend Yield | 0.00% |
| 52-Week High | $155.29 |
| 52-Week Low | $10.81 |
| Volume | 75.44K |
| Avg Volume | 0 |
| Revenue (TTM) | $1.30M |
| Net Income | $-140.06M |
| Gross Margin | 0.00% |
3 analysts cover INBX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $266.67.